

# CE3F4

Catalog No: **tcsc0029107**



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 25mg



## Specifications

**CAS No:**

143703-25-7

**Formula:**

$C_{11}H_{10}Br_2FNO$

**Pathway:**

Others

**Target:**

Others

**Purity / Grade:**

>98%

**Solubility:**

10 mM in DMSO

**Observed Molecular Weight:**


351.01

## Product Description

CE3F4 is a selective antagonist of exchange protein directly activated by cAMP (**Epac1**), with **IC<sub>50</sub>**s of 10.7  $\mu$ M and 66  $\mu$ M for Epac1 and Epac2(B), respectively.

IC50 & Target: IC50: 10.7  $\mu$ M (Epac1), 66  $\mu$ M (Epac2(B))<sup>[1]</sup>

**In Vitro:** CE3F4 is a selective antagonist of Epac1, with IC<sub>50</sub>s of 10.7  $\mu$ M and 66  $\mu$ M for Epac1 and Epac2(B), respectively. CE3F4 is more active on Epac1 than (S)-stereoisomer ((S)-CE3F4, IC<sub>50</sub>, 56  $\mu$ M), but less active than (R)-CE3F4 (IC<sub>50</sub>, 5.8  $\mu$ M). CE3F4 (50  $\mu$ M) shows more inhibitory activities against GEF activity of Epac1, than that of Epac2(AB) or Epac2(B)<sup>[1]</sup>. CE3F4 reduces the exchange activity of Epac1 induced by 007, with IC<sub>50</sub> of  $23 \pm 3$   $\mu$ M. CE3F4 (40  $\mu$ M) specifically inhibits Epac1 guanine nucleotide exchange activity without interference with Rap1 activity or Epac1-Rap1 interaction. CE3F4 has no influence on PKA activity. CE3F4 (20  $\mu$ M) inhibits Epac-induced Rap1 activation in living cultured HEK293 cells<sup>[2]</sup>. CE3F4 (20  $\mu$ M) significantly inhibits the late phase of ERK activation stimulated by glucose in INS-1 cells<sup>[3]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!